|1.||Wang, H: 1 article (06/2000)|
|2.||Feng, Q: 1 article (06/2000)|
|3.||Liu, Y: 1 article (06/2000)|
|4.||He, Y: 1 article (06/2000)|
|5.||Lu, Y: 1 article (06/2000)|
|6.||Wei, L: 1 article (06/2000)|
|7.||Liu, L: 1 article (06/2000)|
|8.||Mäurer, J: 1 article (02/2000)|
|9.||Ebert, W: 1 article (02/2000)|
|10.||Strauss, A: 1 article (02/2000)|
10/01/1987 - "The high relaxivity and apparent avidity of Mn(III)TPPS4 for divergent tumor histologies support the potential use of this agent for improved diagnostic specificity of MR imaging for neoplastic masses."
05/01/1988 - "The isointense model is also extended to predict the field dependence of tumor-specific contrast enhancement by Mn(III)TPPS4."
10/01/1987 - "After administration of Mn(III)TPPS4, all tumors demonstrated significant enhancement of signal intensity that persisted to 24 hours. "
10/01/1987 - "Spin-echo images of 15 mice, five mice for each implanted tumor type, were obtained before and at 20 minutes, and 2, 4, and 24 hours following administration of 0.09 mmol/kg of Mn(III)TPPS4. "
01/01/1987 - "The results indicate that Mn(III)TPPS4 is a useful prototype paramagnetic metalloporphyrin MRI contrast agent with a significant affinity for the L1210 tumor."
|3.||Melanoma (Melanoma, Malignant)
05/01/1999 - "A specific accumulation of the metalloporphyrin Mn-TPPS4 in melanotic melanoma could not be proved. "
05/01/1999 - "The aim of this study was to examine the contrast enhancement of implanted melanotic melanoma after application of Mn-TPPS4 to achieve a better characterization of this malignant skin tumor. "
02/01/2000 - "The aim of this study was to evaluate the potential of the paramagnetic metalloporphyrin Mn-TPPS4 (using Gd-DTPA as the reference) for magnetic resonance imaging (MRI) of pigmented malignant melanoma in an animal model. "
02/01/2000 - "High resolution MRI (2.0 T, 2.0 cm surface coil, T1-weighted FLASH two-dimensional sequence) was performed on 15 mice (C57bl6) with intracutaneous implanted melanoma (B16F1) before and after intravenous administration of Gd-DTPA (Magnevist, Schering AG, Berlin, Germany) and Mn-TPPS4 (Porphyrin Products, Logan, Utah, USA). "
02/01/2000 - "Contrast-enhanced high resolution magnetic resonance imaging of pigmented malignant melanoma using Mn-TPPS4 and Gd-DTPA: experimental results."
10/01/1992 - "T1 snapshot FLASH measurement of rat brain glioma: kinetics of the tumor-enhancing contrast agent manganese (III) tetraphenylporphine sulfonate."
03/01/1993 - "The results also indicate that Mn-BOPP may have a slower uptake in the 9L glioma than Mn-TPPS4 but a longer retention in the tumor. "
|5.||Brain Neoplasms (Brain Tumor)
10/01/1992 - "The ultrafast inversion recovery snapshot FLASH technique was used to determine the kinetics of the contrast agent manganese (III) tetraphenylporphine sulfonate (MnTPPS) in experimental brain tumors in rats. "
01/01/1990 - "The effect of manganese(III)tetraphenylporphine sulfonate (MnTPPS) on the relaxation enhancement of NMR images (MRI) was studied in experimental brain tumors in rats. "
|1.||Reactive Oxygen Species (Oxygen Radicals)
|2.||Gadolinium DTPA (Magnevist)
|3.||tetraphenylporphine sulfonate (TPPS)
|5.||5,10,15,20- tetrakis(4- sulphophenyl)- porphine dodecahydrate
|6.||2,4- (alpha,beta- dihydroxyethyl)deuteroporphyrin IX tetrakiscarborane carboxylate ester